Classes in model | AIC | BIC | SS-BIC | Entropy | VLMR | BLRT | Percentage in each class (in order of size) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Class 1 | Class 2 | Class 3 | Class 4 | Class 5 | Class 6 | |||||||
ERAN cohort | ||||||||||||
 1 | −5458 | −5392 | −5738 | Not available | 100% |  |  |  |  |  | ||
 2 | −5858 | −5753 | −5823 | 0.78 | 2387* | 2387* | 56% | 44% |  |  |  |  |
 3 | −6229 | −6087 | −6182 | 0.81 | 2951* | 2951* | 52% | 33% | 15% |  |  |  |
 4 | −6395 | −6214 | −6335 | 0.80 | 3145** | 3145* | 48% | 27% | 13% | 12% |  |  |
  5 | −6552 | −6333 | −6480 | 0.80 | 3235 *** | 3235 * | 40% | 26% | 13% | 11% | 10% |  |
 6 | −6645 | −6389 | −6560 | 0.82 | 3311 | 3311* | 40% | 26% | 11% | 11% | 10% | 2% |
British Society for Rheumatology Biologics Registers TNF inhibitor cohort | ||||||||||||
 1 | −69,795 | −69,695 | −69,739 | Not available | 100% |  |  |  |  |  | ||
 2 | −77,781 | −77,623 | −77,693 | 0.65 | 36,175* | 36,175* | 62% | 38% |  |  |  |  |
 3 | −79,445 | −79,229 | −79,325 | 0.71 | 38,913** | 38,913* | 53% | 41% | 6% |  |  |  |
  4 | −80,851 | −80,578 | −80,698 | 0.69 | 39,753 * | 39,753 * | 40% | 23% | 21% | 16% |  |  |
 5 | −81,896 | −81,565 | −81,711 | 0.70 | 40,464* | 40,464* | 32% | 24% | 22% | 19% | 2% |  |
British Society for Rheumatology Biologics Registers non-biologic cohort | ||||||||||||
 1 | −19,209 | −19,127 | −19,172 | Not available | 100% |  |  |  |  |  | ||
 2 | −21,497 | −21,368 | −21,438 | 0.70 | 9618* | 9618* | 56% | 44% |  |  |  |  |
 3 | −22,638 | −22,462 | −22,557 | 0.76 | 10,770* | 10,770* | 51% | 34% | 15% |  |  |  |
  4 | −23,170 | −22,947 | −23,068 | 0.76 | 11,349 * | 11,349 * | 51% | 21% | 18% | 10% |  |  |
 5 | −23,457 | −23,188 | −23,334 | 0.76 | 11,623 | 11,623* | 45% | 20% | 19% | 11% | 5% |  |